A Comparison of Multimodality Treatment: Two or Four Courses of Paclitaxel plus Cisplatin or S-1 plus Cisplatin Followed by Surgery for Locally Advanced Gastric Cancer, a Randomized Phase II Trial (COMPASS)

T Yoshikawa, A Tsuburaya, S Morita, Y Kodera, S Ito, H Cho, Y Miyashita and J. Sakamoto

Japanese Journal of Clinical Oncology, 2010, 40(4), 369-372. DOI: 10.1093/jjco/hyp178


This randomized Phase II trial compares neoadjuvant chemotherapy of two or four courses of S-1 (1 M tegafur–0.4 M gimestat–1 M ostat potassium) plus cisplatin or paclitaxel plus cisplatin by a two-by-two factorial design for patients with macroscopically resectable locally advanced gastric cancer. The primary endpoint is the 3-year overall survival. The sample size is 60–80 in a total for two hypotheses of the superiority of four courses to two courses and the superiority of paclitaxel plus cisplatin to S-1 plus cisplatin. In both arms, S-1 is strongly recommended post-operatively for at least 6 months but no adjuvant chemotherapy is permitted other than S-1 until recurrence. This trial could appraise more suitable cycles and regimen as neoadjuvant chemotherapy for gastric cancer.

ASCI-ID: 1152-151